A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis (LUNAR)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT00282347
First received: January 24, 2006
Last updated: January 6, 2015
Last verified: January 2015
  Purpose

This was a Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of rituximab in combination with mycophenolate mofetil (MMF) compared with placebo in combination with MMF in subjects diagnosed with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV lupus nephritis.


Condition Intervention Phase
Lupus Nephritis
Drug: Rituximab
Drug: Placebo
Drug: Mycophenolate mofetil
Drug: Methylprednisolone
Drug: Diphenhydramine
Drug: Acetaminophen
Drug: Prednisone
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis

Resource links provided by NLM:


Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Percentage of Participants Who Achieved a Complete Renal Response (CRR), a Partial Renal Response (PRR), or no Renal Response (NRR) at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
    A participant had a CRR if they met the following 3 criteria: (1) Normalization of serum creatinine (SC) as evidenced by a SC level ≤ the upper limit of the normal range of central laboratory values or a SC level ≤ 15% greater than Baseline, if Baseline SC was within the normal range of the central laboratory values; (2) Inactive urinary sediment (as evidenced by < 5 red blood cells/high-power field (RBCs/HPF) and absence of red cell casts; (3) Urinary protein (UP) to creatinine ratio (CR) < 0.5. A participant had a PRR if they met the following 3 criteria: (1) A SC level ≤ 15% above Baseline; (2) RBCs/HPF ≤ 50% above Baseline and no RBC casts; (3) 50% improvement in the UP to CR, with 1 of the following conditions met: If the Baseline UP to CR was ≤ 3.0, then a UP to CR of < 1.0 or if the Baseline UP to CR was > 3.0, then a UP to CR of ≤ 3.0. A participant had a NRR if they did not achieve either a CRR or PRR.


Secondary Outcome Measures:
  • Percentage of Participants Who Achieved a Complete Renal Response at Week 24 and Maintained it to Week 52 [ Time Frame: Week 24 to Week 52 ] [ Designated as safety issue: No ]
    A participant had a complete renal response if they met the following 3 criteria: (1) Normalization of serum creatinine as evidenced by a serum creatinine level ≤ the upper limit of the normal range of central laboratory values or a serum creatinine level ≤ 15% greater than Baseline, if Baseline serum creatinine was within the normal range of the central laboratory values; (2) Inactive urinary sediment (as evidenced by < 5 red blood cells/high-power field and absence of red cell casts; (3) Urinary protein to creatinine ratio < 0.5.

  • Percentage of Participants Who Achieved a Complete Renal Response at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
    A participant had a complete renal response if they met the following 3 criteria: (1) Normalization of serum creatinine as evidenced by a serum creatinine level ≤ the upper limit of the normal range of central laboratory values or a serum creatinine level ≤ 15% greater than Baseline, if Baseline serum creatinine was within the normal range of the central laboratory values; (2) Inactive urinary sediment (as evidenced by < 5 red blood cells/high-power field and absence of red cell casts; (3) Urinary protein to creatinine ratio < 0.5.

  • Percentage of Participants With a Baseline Urine Protein to Creatinine Ratio of > 3.0 Who Achieved a Urine Protein to Creatinine Ratio of < 1.0 at Week 52 [ Time Frame: Baseline to Week 52 ] [ Designated as safety issue: No ]
  • British Isles Lupus Assessment Group (BILAG) Index Score Over 52 Weeks [ Time Frame: Baseline to Week 52 ] [ Designated as safety issue: No ]
    The BILAG Index assesses 86 clinical signs and symptoms and laboratory measures of systemic lupus erythematosus in 8 organ system domains: General, mucocutaneous, neurological, musculoskeletal, cardiorespiratory, vasculitis, renal, and hematologic. Most of the 86 items are rated on the following scale: 0=Not present, 1=Improving, 2=Same, 3=Worse, 4=New. Some items are rated as either Yes or No. A single alphabetic score of A (very active) through E (not or never active) for each of the 8 domains is determined from the rating of the individual items in each domain. The total BILAG score is the sum of the scores of the 8 domains where A=9, B=3, C=1, D=0, and E=0. The total score ranges from 0 to 72 with a higher score indicating greater lupus activity. To calculate a BILAG score over the 52 week treatment period of the study, the area under the response-time curve of BILAG scores assessed every 4 weeks was divided by the number of days in the time curve minus the Baseline BILAG score.

  • Time to Achieve a Complete Renal Response [ Time Frame: Baseline to Week 52 ] [ Designated as safety issue: No ]
  • Change From Baseline in the Systemic Lupus Erythematosus Expanded Health Survey Physical Function Score at Week 52 [ Time Frame: Baseline to Week 52 ] [ Designated as safety issue: No ]
    The systemic lupus erythematosus Expanded Health Survey is based on the Short Form 36 Health survey with additional questions specific to lupus. The physical function component score of the survey can range from 0-100. A higher score indicates better health. A positive change score indicates improvement.

  • Change From Baseline in Anti-double-stranded DNA at Week 52 [ Time Frame: Baseline to Week 52 ] [ Designated as safety issue: No ]
  • Change From Baseline in C3 and C4 Complement Levels at Week 52 [ Time Frame: Baseline to Week 52 ] [ Designated as safety issue: No ]

Enrollment: 144
Study Start Date: January 2006
Study Completion Date: January 2013
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rituximab
Participants received rituximab 1000 mg intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
Drug: Rituximab
Rituximab was provided as a sterile solution for injection.
Other Names:
  • Rituxan
  • MabThera
  • Zytux
Drug: Mycophenolate mofetil
Other Name: CellCept
Drug: Methylprednisolone Drug: Diphenhydramine Drug: Acetaminophen Drug: Prednisone
Placebo Comparator: Placebo
Participants received placebo intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
Drug: Placebo
Placebo was provided as a sterile solution for injection.
Drug: Mycophenolate mofetil
Other Name: CellCept
Drug: Methylprednisolone Drug: Diphenhydramine Drug: Acetaminophen Drug: Prednisone

Detailed Description:

In addition to receiving study drug (rituximab or placebo), participants in each treatment group received mycophenolate mofetil at a starting dose of 1500 mg/day IV in 3 divided doses and were titrated up by 500 mg/week to 3000 mg/day by Week 4, as tolerated. Participants in each treatment group also received methylprednisolone 1000 mg IV prior to and 3 days following the first study drug infusion and methylprednisolone 100 mg IV prior to the other study drug infusions. Participants in each treatment group also received diphenhydramine 50 mg orally and acetaminophen 1000 mg orally 30-60 minutes prior to each study drug infusion. From Days 2 to 16, participants in each treatment group received prednisone 0.75 mg/kg/day orally (maximum dose of 60 mg) except on the day of the second methylprednisolone dose. On Day 16, a taper was initiated to achieve a dose of 10 mg/day by Week 16.

  Eligibility

Ages Eligible for Study:   16 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of systemic lupus erythematosus (SLE) according to current American College of Rheumatology (ACR) criteria.
  • Diagnosis of International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV lupus nephritis (LN), with either active or active/chronic disease.
  • Proteinuria.
  • 16-75 years of age.

Exclusion Criteria:

  • Retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke or stroke syndrome, cerebellar ataxia, or dementia that is currently active and resulting from SLE.
  • Unstable subjects with thrombocytopenia experiencing or at high risk for developing clinically significant bleeding or organ dysfunction requiring therapies such as plasmapheresis or acute blood or platelet transfusions.
  • Lack of peripheral venous access.
  • Pregnancy or lactation.
  • History of severe allergic or anaphylactic reactions to monoclonal antibodies.
  • Significant or uncontrolled medical disease in any organ system not related to SLE or LN, which, in the investigator's opinion, would preclude subject participation.
  • Concomitant chronic conditions, excluding SLE (eg, asthma, Crohn's disease) that require oral or systemic corticosteroid use in the 52 weeks prior to screening.
  • History of renal transplant.
  • Known human immunodeficiency virus (HIV) infection.
  • Known active infection of any kind (but excluding fungal infection of nail beds) or any major episode of infection requiring hospitalization or treatment with intravenous anti-infectives within 4 weeks of randomization or oral anti-infectives within 2 weeks of randomization.
  • History of deep space infection within 1 year of screening.
  • History of serious recurrent or chronic infection.
  • History of cancer, including solid tumors, hematological malignancies, and carcinoma in situ (except basal cell carcinomas of the skin that have been treated or excised and have resolved).
  • Currently active alcohol or drug abuse or history of alcohol or drug abuse within 52 weeks prior to screening.
  • Major surgery requiring hospitalization within 4 weeks of screening (excluding diagnostic surgery).
  • Treatment with cyclophosphamide or calcineurin inhibitors within the 90 days prior to screening.
  • Use of mycophenolate mofetil (MMF) at a dose of > 2 grams daily for longer than the 90 days prior to screening.
  • Intolerance or history of allergic reaction to MMF.
  • Intolerance or history of allergic reaction to both angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers.
  • Use of oral prednisone (or corticosteroid equivalent) at a dose of > 20 mg/day for longer than the 14 days prior to screening.
  • Previous treatment with CAMPATH-1H (alemtuzumab).
  • Previous treatment with a B-cell targeted therapy.
  • Treatment with any investigational agent (including biologic agents approved for other indications) within 28 days of the start of the screening period or 5 half-lives of the investigational drug (whichever is longer).
  • Receipt of a live vaccine within the 28 days prior to screening.
  • Intolerance or contraindication to oral or IV corticosteroids.
  • Current therapy with a nonsteroidal anti-inflammatory agent.
  • Positive hepatitis B sAg or hepatitis C serology.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00282347

Sponsors and Collaborators
Genentech, Inc.
Investigators
Study Director: Paul Brunetta, MD Genentech, Inc.
  More Information

No publications provided by Genentech, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT00282347     History of Changes
Other Study ID Numbers: U2970g
Study First Received: January 24, 2006
Results First Received: February 1, 2010
Last Updated: January 6, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Genentech, Inc.:
Class IV LN
Lupus
LUNAR
LN

Additional relevant MeSH terms:
Lupus Nephritis
Nephritis
Autoimmune Diseases
Connective Tissue Diseases
Glomerulonephritis
Immune System Diseases
Kidney Diseases
Lupus Erythematosus, Systemic
Urologic Diseases
Acetaminophen
Diphenhydramine
Methylprednisolone
Methylprednisolone Hemisuccinate
Methylprednisolone acetate
Mycophenolate mofetil
Mycophenolic Acid
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Prednisone
Promethazine
Rituximab
Analgesics
Analgesics, Non-Narcotic
Anesthetics
Anesthetics, Local
Anti-Allergic Agents
Anti-Inflammatory Agents
Antibiotics, Antineoplastic

ClinicalTrials.gov processed this record on May 04, 2015